Repository logo
 

Cancer Cell’s Achilles Heels: Considerations for Design of Anti-Cancer Drug Combinations

Date

2024-12

Authors

Gahramanov, Valid
Vizeacoumar, Frederick Sagayaraj
Morales, Alain Morejon
Bonham, Keith
Sakharkar, Meena K.
Kumar, Santosh
Vizeacoumar, Franco
Freywald, Andrew
Sherman, Michael

Journal Title

Journal ISSN

Volume Title

Publisher

International Journal of Molecular Sciences

ORCID

Type

Article

Degree Level

Abstract

Loss of function screens using shRNA (short hairpin RNA) and CRISPR (clustered regularly interspaced short palindromic repeats) are routinely used to identify genes that modulate responses of tumor cells to anti-cancer drugs. Here, by integrating GSEA (Gene Set Enrichment Analysis) and CMAP (Connectivity Map) analyses of multiple published shRNA screens, we identified a core set of pathways that affect responses to multiple drugs with diverse mechanisms of action. This suggests that these pathways represent “weak points” or “Achilles heels”, whose mild disturbance should make cancer cells vulnerable to a variety of treatments. These “weak points” include proteasome, protein synthesis, RNA splicing, RNA synthesis, cell cycle, Akt-mTOR, and tight junction-related pathways. Therefore, inhibitors of these pathways are expected to sensitize cancer cells to a variety of drugs. This hypothesis was tested by analyzing the diversity of drugs that synergize with FDA-approved inhibitors of the proteasome, RNA synthesis, and Akt-mTOR pathways. Indeed, the quantitative evaluation indicates that inhibitors of any of these signaling pathways can synergize with a more diverse set of pharmaceuticals, compared to compounds inhibiting targets distinct from the “weak points” pathways. Our findings described here imply that inhibitors of the “weak points” pathways should be considered as primary candidates in a search for synergistic drug combinations.

Description

Keywords

shRNA screening, GSEA, drug combination, CMAP, signaling pathway, synergy

Citation

Degree

Department

Program

Advisor

Committee

Part Of

item.page.relation.ispartofseries

DOI

https://doi.org/10.3390/ijms252413495

item.page.identifier.pmid

item.page.identifier.pmcid